Novartis says it overpaid Roche's Genentech nearly $210 million in a licensing deal—and it wants its money back

For years, Novartis said it dutifully shelled out tens of millions to Genentech as part of a patent licensing deal that dated back to 2005. Later, the Swiss pharma discovered it accidentally overpaid by nearly $210 million.

Those are the central arguments in a lawsuit filed by Novartis against its Swiss pharma counterpart seeking $209.5 million. In the suit, which recently made its way to California federal court, Novartis says Genentech isn't coughing up the dough.